Related Experiment Videos
Strontium as therapy for osteoporosis.
1INSERM U606 and University Paris 7, Lariboisière Hospital, 2 Rue Ambroise Paré, 75475 Paris cedex 10, France. pierre.marie@larib.Inserm.fr
Current Opinion in Pharmacology
|September 27, 2005
Summary
Strontium ranelate effectively treats postmenopausal osteoporosis by reducing bone resorption and enhancing bone formation. Clinical studies confirm its ability to lower fracture risk in women with osteoporosis.
Area of Science:
- Bone Biology and Pharmacology
- Osteoporosis Treatment
Background:
- Osteoporosis is a condition of low bone mass leading to increased fracture risk.
- Current treatments aim to slow bone loss, but novel agents with anabolic effects are needed.
Purpose of the Study:
- To evaluate the anti-osteoporotic effects of strontium ranelate.
- To assess its impact on bone cells and clinical outcomes in postmenopausal osteoporosis.
Main Methods:
- In vitro studies on osteoclast and osteoblast activity.
- In vivo animal studies assessing bone mass and microarchitecture.
- Clinical trials in postmenopausal women with osteoporosis.
Main Results:
- Strontium ranelate inhibits bone resorption and promotes bone formation in vitro.
- Animal studies showed increased bone mass, improved microarchitecture, and enhanced strength.
- Clinical trials demonstrated a reduced risk of vertebral and non-vertebral fractures.
Conclusions:
- Strontium ranelate exhibits unique dual effects on bone cells, promoting formation and inhibiting resorption.
- Strontium ranelate offers significant clinical benefits for treating postmenopausal osteoporosis and reducing fracture risk.